Effective February 23, 2026, every clinician who inserts or removes the Nexplanon contraceptive implant must be certified under a new FDA-mandated REMS program, per the updated labeling the FDA approved on January 16, 2026. REMS — a Risk Evaluation and Mitigation Strategy — is the strongest safety infrastructure the agency can attach to a drug, and applying it to a routine contraceptive changes the logistics of getting the implant. This site publishes information, not medical advice; for scheduling and placement, your own clinician remains the right contact.
What REMS means for this implant
Nexplanon is a matchstick-sized rod placed under the skin of the upper arm that releases etonogestrel and prevents pregnancy for up to five years; it is among the most effective reversible contraceptives available, with a typical-use failure rate under 1 percent, per CDC contraception guidance, 2024. Its known procedural risks — nerve or vessel injury during insertion, and non-removable or migrated rods in rare cases — are what the new program targets. Per the January 16, 2026 label update, providers must complete training and register in the REMS system before placing or removing implants.
Related stories: FDA approves Gwyn Lo, a once-weekly low-dose contraceptive patch · WIC is funded through September 2026, with produce benefits intact.
What changes at the clinic level
Previously, certification was a one-time training from the manufacturer that most inserters completed years ago; under the REMS, enrollment is verified before product is shipped to a practice. Clinics that placed implants routinely will keep doing so once enrolled. The practical friction falls on low-volume prescribers — some family medicine and pediatric practices — who must complete certification before their next insertion. Professional groups including the Society of Family Planning posted provider guidance in February 2026 on maintaining access during the transition, and publicly funded clinics reported completing enrollment in waves through the spring.
What it means if you have an implant — or want one
If your implant is in place, nothing about it has changed: the device itself is the same, and removal still happens on request at any time. If you are due for an insertion or replacement in 2026, expect scheduling staff to confirm the clinician's REMS enrollment; in some practices a certified colleague may perform the procedure instead of your usual prescriber. No one should be told removal now requires justification — it does not.
The point most coverage skipped
REMS programs almost always attach to drugs with overdose or fetal-toxicity potential, and they have historically functioned as access bottlenecks — the mifepristone REMS being the clearest example. Applying the framework to a widely used contraceptive sets a marker: safety infrastructure is migrating from dangerous drugs to routine devices. Whether it reduces the rare insertion injuries without thinning the pool of certified providers is the outcome to watch in 2026–2027 access data.